Neuroscience Team Recognized as Unit of Distinction

Translate to Spanish or other 102 languages!

Colleagues from RGRH’s Critical Care - Progressive Care Unit, Recipient of HCA Healthcare’s the Neuroscience Unit of Distinction. Courtesy Photo RGRH
Colleagues from RGRH’s Critical Care – Progressive Care Unit, Recipient of HCA Healthcare’s the Neuroscience Unit of Distinction. Courtesy Photo RGRH

Mega Doctor News

- Advertisement -

McALLEN, Texas – Rio Grande Regional Hospital (RGRH) is proud and excited to announce that the Neuroscience team was recently recognized as a Recipient of the HCA Healthcare Critical Care – Progressive Care Unit of Distinction.  A total of 202 nursing units from across the country were recognized as top-performing nursing units. 

Units of Distinction are categorized in the top five percent of all HCA Healthcare medical-surgical, critical care, emergency services, surgical services, behavioral health, women’s and children’s nursing units, pediatrics/PICU, and inpatient rehabilitation units.  The top six to 10  percent of all HCA Healthcare units earned honorable mention designations. Our quality of care includes a multidisciplinary approach that consists of emergency room physicians, vascular-trained neurologists available 24-7, neurosurgeons, cardiologists, and an excellent rehabilitation team. 

Congratulations to the Neuroscience team for raising the bar and for their continued commitment to our mission, “Above all else, we are committed to the care and improvement of human life.”  

- Advertisement -

To learn more about the Stroke and Neurosciences programs, visit RioHealth.com.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

STHS Children’s Marks 20th Anniversary with Gala Honoring Pediatric Providers Behind Its Success

For the past 20 years, South Texas Health System Children’s has stood as a place where compassionate care and clinical excellence come together to create hope for children and their families.
- Advertisement -